

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

(Rs. in Lakhs)

	Particulars	3 months ended	Preceding 3	Corresponding	Year ended
		30.06.2024	months ended	3 months	ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
			(Refer Note 2)		
	Income				
1	Revenue from operations	81100	91087	73802	340725
2	Other income	3585	2987	3680	12348
3	Total Income (1+2)	84685	94074	77482	353073
	Expenses				
(a)	Cost of materials consumed	13333	19229	14547	50499
(b)	Purchases of stock-in-trade	17274	25574	17420	85308
(c)	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1326)	(9890)	(4438)	(6964)
(d)	Employee benefits expense	15128	17283	16500	62439
(e)	Finance costs	37	77	28	180
(f)	Depreciation and amortisation expense	1641	1810	1636	6968
(g)	Other expenses	13749	13360	15648	59378
4	Total expenses	59836	67443	61341	257808
5	Profit before exceptional items and tax (3-4)	24849	26631	16141	95265
6	Exceptional items [credit/(charge)] (Refer Note 4)	-	240	1730	(14361)
7	Profit before tax (5+6)	24849	26871	17871	80904
8	Tax expense				
(a)	Current tax	6333	6116	5263	23571
(b)	Deferred tax	351	1447	(450)	(1136)
9	Profit for the period/year (7-8)	18165	19308	13058	58469

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2024

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2024	Preceeding 3 months ended 31.03.2024	Corresponding 3 months ended 30.06.2023	Year ended 31.03.2024
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited)
10	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss	-	(91)	-	(557)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	22	-	140
11	Total comprehensive income for the period (9+10)	18165	19239	13058	58052
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				161468
	Earnings per share (EPS) (of Rs. 10 each)				
	Basic and diluted EPS before Exceptional items (Rs.)	10.72	11.29	6.94	40.83
	Basic and diluted EPS after Exceptional items (Rs.)	10.72	11.39	7.71	34.51
		Not Annualised			

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 02nd August 2024. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June 2024.
2. The figures for the 3 months ended 31st March 2024 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2024.
- 3 Dividend of Rs. 32 per equity share for the year ended 31st March 2024 had been approved by the shareholders in the Annual General meeting held on 28th June 2024.
- 4 Exceptional items pertaining to prior period / year :
 - (a) Exceptional items credit for the quarter ended 30th June 2023 of Rs.1730 lakhs (Quarter ended 31st March 2024 Rs. 240 lakhs) is on account of profit on sale of surplus residential properties.
 - (b) Exceptional items charge for the year ended 31st March 2024 of Rs.14361 lakhs is on account of charge of Rs. 16331 lakhs on account of one off VRS (Voluntary Retirement Scheme) cost including other employee dues of Rs. 5537 lakhs and profit on sale of surplus residential properties of Rs. 1970 lakhs.
5. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

02nd August, 2024

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346